Diastolic Dysfunction in Individuals With Human Immunodeficiency Virus Infection: Literature Review, Rationale and Design of the Characterizing Heart Function on Antiretroviral Therapy (CHART) Study.

[1]  M. Lederman,et al.  Prospective Analysis of Lipid Composition Changes with Antiretroviral Therapy and Immune Activation in Persons Living with HIV , 2017, Pathogens & immunity.

[2]  Sanjiv J. Shah,et al.  Clinical characteristics of HIV-infected patients with adjudicated heart failure , 2017, European journal of preventive cardiology.

[3]  Kaleab Z. Abebe,et al.  Temporal Relation Between Myocardial Fibrosis and Heart Failure With Preserved Ejection Fraction: Association With Baseline Disease Severity and Subsequent Outcome , 2017, JAMA cardiology.

[4]  Olga V. Patterson,et al.  Association Between HIV Infection and the Risk of Heart Failure With Reduced Ejection Fraction and Preserved Ejection Fraction in the Antiretroviral Therapy Era: Results From the Veterans Aging Cohort Study , 2017, JAMA cardiology.

[5]  Sanjiv J. Shah,et al.  A Test in Context: E/A and E/e' to Assess Diastolic Dysfunction and LV Filling Pressure. , 2017, Journal of the American College of Cardiology.

[6]  Patrizio Lancellotti,et al.  Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2016, European heart journal cardiovascular Imaging.

[7]  Michael T. Lu,et al.  Subclinical myocyte injury, fibrosis and strain in relationship to coronary plaque in asymptomatic HIV-infected individuals , 2016, AIDS.

[8]  M. Egger,et al.  Trends in life expectancy of HIV-positive adults on antiretroviral therapy across the globe: comparisons with general population , 2016, Current opinion in HIV and AIDS.

[9]  Eike Nagel,et al.  T1 Mapping in Characterizing Myocardial Disease: A Comprehensive Review. , 2016, Circulation research.

[10]  J. Todd,et al.  Short-term and long-term cardiovascular risk, metabolic syndrome and HIV in Tanzania , 2016, Heart.

[11]  D. Douek,et al.  Gut barrier structure, mucosal immunity and intestinal microbiota in the pathogenesis and treatment of HIV infection , 2016, AIDS Research and Therapy.

[12]  A. Kengne,et al.  A Meta-Analysis of the Metabolic Syndrome Prevalence in the Global HIV-Infected Population , 2016, PloS one.

[13]  J. Gieseke,et al.  Cardiac Magnetic Resonance Reveals Signs of Subclinical Myocardial Inflammation in Asymptomatic HIV-Infected Patients , 2016, Circulation. Cardiovascular imaging.

[14]  J. Ananworanich,et al.  Immune activation during acute HIV infection and the impact of early antiretroviral therapy , 2016, Current opinion in HIV and AIDS.

[15]  S. Piechnik,et al.  HIV-1–Related Cardiovascular Disease Is Associated With Chronic Inflammation, Frequent Pericardial Effusions, and Probable Myocardial Edema , 2016, Circulation. Cardiovascular imaging.

[16]  M. Budoff,et al.  Non-Classical Monocytes and Monocyte Chemoattractant Protein-1 (MCP-1) Correlate with Coronary Artery Calcium Progression in Chronically HIV-1 Infected Adults on Stable Antiretroviral Therapy , 2016, PloS one.

[17]  G. Bloomfield,et al.  The Causes of HIV-Associated Cardiomyopathy: A Tale of Two Worlds , 2016, BioMed research international.

[18]  Sanjiv J. Shah,et al.  Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone , 2015, Circulation.

[19]  Jeffrey N. Martin,et al.  Novel Biomarkers of Cardiac Stress, Cardiovascular Dysfunction, and Outcomes in HIV-Infected Individuals. , 2015, JACC. Heart failure.

[20]  T. Hallett,et al.  Future challenges for clinical care of an ageing population infected with HIV: a modelling study , 2015, The Lancet. Infectious diseases.

[21]  D. Bluemke,et al.  Abnormal Myocardial Function Is Related to Myocardial Steatosis and Diffuse Myocardial Fibrosis in HIV-Infected Adults. , 2015, The Journal of infectious diseases.

[22]  A. Bayés‐Genís,et al.  Structural heart disease and ST2: cross-sectional and longitudinal associations with echocardiography. , 2015, The American journal of cardiology.

[23]  M. Gladwin,et al.  Elevated NT-Pro-Brain Natriuretic Peptide Level Is Independently Associated with All-Cause Mortality in HIV-Infected Women in the Early and Recent HAART Eras in the Women’s Interagency HIV Study Cohort , 2015, PloS one.

[24]  D. Dey,et al.  Increased pericardial fat accumulation is associated with increased intramyocardial lipid content and duration of highly active antiretroviral therapy exposure in patients infected with human immunodeficiency virus: a 3T cardiovascular magnetic resonance feasibility study , 2015, Journal of Cardiovascular Magnetic Resonance.

[25]  A. Leite-Moreira,et al.  HIV Patients Have Impaired Diastolic Function that is Not Aggravated by Anti-Retroviral Treatment , 2015, Cardiovascular Drugs and Therapy.

[26]  G. Pedrizzetti,et al.  Definitions for a common standard for 2D speckle tracking echocardiography: consensus document of the EACVI/ASE/Industry Task Force to standardize deformation imaging. , 2015, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[27]  S. Solomon,et al.  Left Atrium in Heart Failure With Preserved Ejection Fraction: Structure, Function, and Significance , 2014, Circulation. Heart failure.

[28]  V. Ortiz de la Tabla,et al.  Coinfection with Human Herpesvirus 8 Is Associated with Persistent Inflammation and Immune Activation in Virologically Suppressed HIV-Infected Patients , 2014, PloS one.

[29]  D. Duprez,et al.  Severity of Cardiovascular Disease Outcomes Among Patients With HIV Is Related to Markers of Inflammation and Coagulation , 2014, Journal of the American Heart Association.

[30]  A. Huang,et al.  Prospective echocardiographic assessment of cardiac structure and function in Chinese persons living with HIV. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  J. Butler,et al.  Heart Failure in Patients With Human Immunodeficiency Virus Infection: Epidemiology, Pathophysiology, Treatment, and Future Research , 2014, Circulation.

[32]  Y. Izumiya,et al.  Growth differentiation factor-15 is a useful prognostic marker in patients with heart failure with preserved ejection fraction. , 2014, The Canadian journal of cardiology.

[33]  Milton Packer,et al.  Impaired systolic function by strain imaging in heart failure with preserved ejection fraction. , 2014, Journal of the American College of Cardiology.

[34]  M. Essop,et al.  HIV protease inhibitors and onset of cardiovascular diseases: a central role for oxidative stress and dysregulation of the ubiquitin-proteasome system. , 2014, Biochimica et biophysica acta.

[35]  S. Piechnik,et al.  Comprehensive Cardiac Magnetic Resonance Imaging and Spectroscopy Reveal a High Burden of Myocardial Disease in HIV Patients , 2013, Circulation.

[36]  W. Paulus,et al.  A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. , 2013, Journal of the American College of Cardiology.

[37]  H. Ullum,et al.  Persisting Inflammation and Chronic Immune Activation but Intact Cognitive Function in HIV-Infected Patients After Long-Term Treatment With Combination Antiretroviral Therapy , 2013, Journal of acquired immune deficiency syndromes.

[38]  M. Obokata,et al.  Incremental diagnostic value of la strain with leg lifts in heart failure with preserved ejection fraction. , 2013, JACC. Cardiovascular imaging.

[39]  H. Ullum,et al.  Persistent Inflammation and Endothelial Activation in HIV-1 Infected Patients after 12 Years of Antiretroviral Therapy , 2013, PloS one.

[40]  F. Gaita,et al.  Cardiac dysfunction in pauci symptomatic human immunodeficiency virus patients: a meta-analysis in the highly active antiretroviral therapy era. , 2013, European heart journal.

[41]  D. Margolis,et al.  Antiretroviral Therapy Initiated During Acute HIV Infection Fails to Prevent Persistent T-Cell Activation , 2013, Journal of acquired immune deficiency syndromes.

[42]  David S. Wishart,et al.  HMDB 3.0—The Human Metabolome Database in 2013 , 2012, Nucleic Acids Res..

[43]  W. W. Tang,et al.  Prognostic value of cardiac troponin in chronic stable heart failure: a systematic review , 2012, Heart.

[44]  P. Kellman,et al.  Association Between Extracellular Matrix Expansion Quantified by Cardiovascular Magnetic Resonance and Short-Term Mortality , 2012, Circulation.

[45]  S. Abbara,et al.  Arterial inflammation in patients with HIV. , 2012, JAMA.

[46]  E. Rosenberg,et al.  Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients. , 2011, The Journal of infectious diseases.

[47]  V. Roger,et al.  Progression of left ventricular diastolic dysfunction and risk of heart failure. , 2011, JAMA.

[48]  James D. Thomas,et al.  Mortality rate in patients with diastolic dysfunction and normal systolic function. , 2011, Archives of internal medicine.

[49]  W. Kop,et al.  Prognostic utility of ST2 in patients with acute dyspnea and preserved left ventricular ejection fraction. , 2011, Clinical chemistry.

[50]  L. Kuller,et al.  N-terminal-proB-type natriuretic peptide predicts cardiovascular disease events in HIV-infected patients , 2011, AIDS.

[51]  O. Beran,et al.  Antiretroviral treatment of HIV infection does not influence HIV-specific immunity but has an impact on non-specific immune activation. , 2011, Current HIV research.

[52]  J. Gottdiener,et al.  High Prevalence of Echocardiographic Abnormalities among HIV-infected Persons in the Era of Highly Active Antiretroviral Therapy. , 2011, Clinical Infectious Diseases.

[53]  Stefan Neubauer,et al.  Shortened Modified Look-Locker Inversion recovery (ShMOLLI) for clinical myocardial T1-mapping at 1.5 and 3 T within a 9 heartbeat breathhold , 2010, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.

[54]  R. Nishimura,et al.  Exercise Hemodynamics Enhance Diagnosis of Early Heart Failure With Preserved Ejection Fraction , 2010, Circulation. Heart failure.

[55]  Geoffrey S Ginsburg,et al.  Association of a Peripheral Blood Metabolic Profile With Coronary Artery Disease and Risk of Subsequent Cardiovascular Events , 2010, Circulation. Cardiovascular genetics.

[56]  Jeffrey N. Martin,et al.  Impact of HIV Infection on Diastolic Function and Left Ventricular Mass , 2010, Circulation. Heart failure.

[57]  O. Fiehn,et al.  FiehnLib: mass spectral and retention index libraries for metabolomics based on quadrupole and time-of-flight gas chromatography/mass spectrometry. , 2009, Analytical chemistry.

[58]  P. Massip,et al.  HIV-1 Residual Viremia Correlates with Persistent T-Cell Activation in Poor Immunological Responders to Combination Antiretroviral Therapy , 2009, PloS one.

[59]  G. McComsey,et al.  Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[60]  B. Fevang,et al.  Homeostatic chemokines CCL19 and CCL21 promote inflammation in human immunodeficiency virus‐infected patients with ongoing viral replication , 2009, Clinical and experimental immunology.

[61]  D. J. Veldhuisen,et al.  Galectin‐3: a novel mediator of heart failure development and progression , 2009, European journal of heart failure.

[62]  A. Cohen,et al.  Subclinical cardiac abnormalities in human immunodeficiency virus-infected men receiving antiretroviral therapy. , 2008, The American journal of cardiology.

[63]  Vilmundur Gudnason,et al.  Long-Term Interleukin-6 Levels and Subsequent Risk of Coronary Heart Disease: Two New Prospective Studies and a Systematic Review , 2008, PLoS medicine.

[64]  D. Bluemke,et al.  Arterial Stiffness Is Associated With Regional Ventricular Systolic and Diastolic Dysfunction: The Multi-Ethnic Study of Atherosclerosis , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[65]  W. Abhayaratna,et al.  Characteristics of left ventricular diastolic dysfunction in the community: an echocardiographic survey , 2006, Heart.

[66]  T. Marwick,et al.  Relation of arterial stiffness to diastolic dysfunction in hypertensive heart disease , 2005, Heart.

[67]  J. Schaper,et al.  Matrix metalloproteinases and their tissue inhibitors in pressure-overloaded human myocardium during heart failure progression. , 2004, Journal of the American College of Cardiology.

[68]  K. Bailey,et al.  Plasma Brain Natriuretic Peptide to Detect Preclinical Ventricular Systolic or Diastolic Dysfunction: A Community-Based Study , 2004, Circulation.

[69]  G. Baxter.  The natriuretic peptides , 2004, Basic Research in Cardiology.

[70]  H. Hense,et al.  Prevalence of left ventricular diastolic dysfunction in the community. Results from a Doppler echocardiographic-based survey of a population sample. , 2003, European heart journal.

[71]  K. Dingemans,et al.  Cardiomyopathy with mitochondrial damage associated with nucleoside reverse-transcriptase inhibitors. , 2002, The New England journal of medicine.

[72]  James B Seward,et al.  Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. , 2002, Journal of the American College of Cardiology.

[73]  R. Kronmal,et al.  Multi-Ethnic Study of Atherosclerosis: objectives and design. , 2002, American journal of epidemiology.

[74]  G. d’Ettorre,et al.  Matrix Metalloproteinase-9 and Tissue Inhibitors of Matrix Metalloproteinase-1 in Plasma of Patients Co-Infected with HCV and HIV , 2002, HIV clinical trials.

[75]  Y. Benjamini,et al.  Controlling the false discovery rate in behavior genetics research , 2001, Behavioural Brain Research.

[76]  S. Stein,et al.  Deconvolution gas chromatography/mass spectrometry of urinary organic acids--potential for pattern recognition and automated identification of metabolic disorders. , 1999, Rapid communications in mass spectrometry : RCM.

[77]  J. Smeitink,et al.  Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway , 1998, AIDS.